What is the 13F Pro Quality Score for PSTV?

13F Pro ranks PLUS THERAPEUTICS, INC. (PSTV) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PSTV's current score at https://13fpro.ai/research/PSTV (free sign-up required for the full ranking).

Where does 13F Pro source PSTV data?

All PLUS THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. PLUS THERAPEUTICS, INC. files with the SEC under CIK 1095981. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PSTV in?

PLUS THERAPEUTICS, INC. (PSTV) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PSTV research updated on 13F Pro?

PSTV's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PLUS THERAPEUTICS, INC.(PSTV)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1095981 PSTV stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $8.7M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PSTV Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PLUS THERAPEUTICS, INC. (PSTV), a Healthcare sector company. PSTV is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $8.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), PLUS THERAPEUTICS, INC. reports quarterly revenue of $1.0M, net income of $-6.9M, free cash flow of $-7.1M. Top institutional holders of PSTV by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT,, BlackRock,, based on the most recent SEC filings. PSTV trades on the Nasdaq exchange and files with the SEC under CIK 1095981. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PSTV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PLUS THERAPEUTICS, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$1.0M

Net Income

Q1 2026

$-6.9M

Free Cash Flow

Q1 2026

$-7.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+6.1% YoY

$5.2MFY 2025

FY21 —FY22 —FY23 $4.9MFY25 $5.2M

Net Income

-68.1% YoY

$-22.4MFY 2025

FY21 $-13.4MFY22 $-20.3MFY23 $-13.3MFY25 $-22.4M

Operating Income

-14.8% YoY

$-15.3MFY 2025

FY21 $-12.5MFY22 $-19.7MFY23 $-13.3MFY25 $-15.3M

EPS (Diluted)

+93.2% YoY

$-0.29FY 2025

FY21 $-0.58FY22 $-6.03FY23 $-4.24FY25 $-0.29

Total Assets

+43.4% YoY

$16.3MFY 2025

FY21 $22.0MFY22 $23.9MFY23 $11.4MFY25 $16.3M

Total Debt

—FY 2025

FY21 $6.6MFY22 $5.4MFY23 $4.0MFY25 —

Op. Cash Flow

-61.7% YoY

$-20.8MFY 2025

FY21 $-10.3MFY22 $-13.0MFY23 $-12.9MFY25 $-20.8M

Metric	FY 2025	FY 2023	FY 2022	FY 2021	FY 2020	FY 2018
Revenue	$5.2M +6.1%	$4.9M	—	—	—	$3.7M
Net Income	$-22.4M -68.1%	$-13.3M +34.3%	$-20.3M -51.3%	$-13.4M -62.6%	$-8.2M +34.8%	$-12.6M
Operating Income	$-15.3M -14.8%	$-13.3M +32.4%	$-19.7M -57.8%	$-12.5M -30.3%	$-9.6M -9.4%	$-8.8M
EPS (Diluted)	$-0.29 +93.2%	$-4.24 +29.7%	$-6.03 -943.3%	$-0.58	—	—
Total Assets	$16.3M +43.4%	$11.4M -52.3%	$23.9M +8.6%	$22.0M +81.6%	$12.1M -49.5%	$24.0M
Total Debt	—	$4.0M -26.3%	$5.4M -18.4%	$6.6M +4.4%	$6.3M -55.4%	$14.2M
Operating Cash Flow	$-20.8M -61.7%	$-12.9M +0.9%	$-13.0M -26.2%	$-10.3M -21.9%	$-8.4M +29.6%	$-12.0M

AI Insight: PSTV Financial Trends

PSTV remains pre-revenue with persistent operating losses; equity swung from negative $24M to positive $12M but cash burn continues unabated.

• Revenue stabilized at $1M per quarter from Q1 2025 onward, but operating losses widened to $7M in Q1 2026 from $2M in Q2 2025.

• Equity recovered from $24M deficit in Q1 2025 to $12M positive in Q1 2026, likely via capital raise, but masks deteriorating operations.

• Operating cash flow remained negative every quarter; Q1 2026 burned $6M, consistent with prior-quarter run rate.

⚠ Net income swung wildly: $5M profit in Q2 2025 followed by losses of $4M–$7M; sustainability of Q2 2025 anomaly unclear.

⚠ Operating income deteriorated to $7M loss in Q1 2026 from $2M loss in Q2 2025; operating leverage not evident despite flat revenue.

AI Insight: PSTV Ratio Trends

Plus Therapeutics remains deeply unprofitable with sparse profitability data; ROA deteriorated to -94.8% in Q3 2025.

• Operating margin was -110.7% in Q2 2025, indicating severe cash burn relative to revenue.

• TTM ROE and ROA both deeply negative (-99.8% and -59.9% respectively as of Q1 2026).

⚠ ROA worsened to -94.8% in Q3 2025 from prior periods; monitor for path to profitability.

⚠ Majority of quarters lack reported margins or returns; visibility into operational performance is limited.

Get alerted when PSTV's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PLUS THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PSTV

VANGUARD CAPITAL MANAGEMENT LLC
$395.6K2,427,098 sh
GEODE CAPITAL MANAGEMENT, LLC
$328.0K2,016,314 sh
BlackRock, Inc.
$288.8K1,776,372 sh
VANGUARD FIDUCIARY TRUST CO
$189.7K1,163,776 sh
STATE STREET CORP
$76.2K468,893 sh
NORTHERN TRUST CORP
$47.7K293,300 sh
MILLENNIUM MANAGEMENT LLC
$44.2K271,599 sh
TWO SIGMA SECURITIES, LLC
$23.2K142,812 sh
XTX Topco Ltd
$18.9K116,023 sh
CITIGROUP INC
$15.1K93,002 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$395.6K	2,427,098
GEODE CAPITAL MANAGEMENT, LLC	$328.0K	2,016,314
BlackRock, Inc.	$288.8K	1,776,372
VANGUARD FIDUCIARY TRUST CO	$189.7K	1,163,776
STATE STREET CORP	$76.2K	468,893
NORTHERN TRUST CORP	$47.7K	293,300
MILLENNIUM MANAGEMENT LLC	$44.2K	271,599
TWO SIGMA SECURITIES, LLC	$23.2K	142,812
XTX Topco Ltd	$18.9K	116,023
CITIGROUP INC	$15.1K	93,002

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PSTV on your watchlist

Track score changes the day PLUS THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PSTV a good stock to buy?

13F Pro's AI-powered analysis of PLUS THERAPEUTICS, INC. (PSTV) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PSTV are available on the PSTV stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PSTV?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PSTV. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PLUS THERAPEUTICS, INC.'s investment landscape.